Keybanc Maintains Overweight on Repligen, Lowers Price Target to $210
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Paul Knight has maintained an Overweight rating on Repligen (NASDAQ:RGEN) but lowered the price target from $240 to $210.
November 01, 2023 | 9:41 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Repligen's price target has been lowered from $240 to $210 by Keybanc, though the Overweight rating is maintained.
The news is directly about Repligen and is likely to influence investor sentiment. While the Overweight rating indicates that Keybanc still sees the stock as a good investment, the lowered price target may cause some investors to reassess their positions, potentially leading to short-term price volatility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100